Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 4:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,934 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Metastasis Skin Clear all
Completed No phase listed Observational Results available

Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.

NCT04460911
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Sep 11, 2026, 4:37 AM EDT
Terminated Phase 2 Interventional Results available

Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer

NCT00546364
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2, Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2, Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
60
States / cities
Tuscaloosa, Alabama • La Jolla, California • Southington, Connecticut + 52 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Phase 2 Interventional

Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer

NCT00216021
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Capecitabine, Oxaliplatin
Drug
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
11
States / cities
Newark, Delaware • Galesburg, Illinois • Elkhart, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Sep 11, 2026, 4:37 AM EDT
Active, not recruiting Phase 1 Interventional

T-Cell Therapy for Advanced Breast Cancer

NCT02792114
View directory record Official record
Conditions
Breast Cancer, Metastatic HER2-negative Breast
Interventions
Cyclophosphamide, Mesothelin-targeted T cells, AP1903
Drug · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 11, 2026, 4:37 AM EDT
Terminated Phase 1 Interventional

A Study of ASP1012 in Adults With Solid Tumors

NCT06171178
View directory record Official record
Conditions
Solid Tumor
Interventions
ASP1012, Pembrolizumab
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
8
States / cities
Los Angeles, California • Newport Beach, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer

NCT03853707
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Atezolizumab, Capecitabine, Carboplatin, Ipatasertib, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Phase 2 Interventional Results available

QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer

NCT00626106
View directory record Official record
Conditions
Breast Cancer, Breast Tumors, Metastatic Cancer
Interventions
AMG 479, Placebo
Drug
Lead sponsor
NantCell, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
25
States / cities
Chandler, Arizona • Anaheim, California • Beverly Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 11, 2026, 4:37 AM EDT
Withdrawn Phase 1Phase 2 Interventional

A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer

NCT06938711
View directory record Official record
Conditions
Breast Cancer
Interventions
Elacestrant, Onapristone
Drug
Lead sponsor
Context Therapeutics Inc.
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 21, 2025 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Phase 1 Interventional

PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer

NCT03166085
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
PU-H71, Nab-paclitaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 19, 2021 · Synced Sep 11, 2026, 4:37 AM EDT
Terminated Phase 1 Interventional

Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

NCT03742349
View directory record Official record
Conditions
Triple Negative Breast Cancer (TNBC)
Interventions
spartalizumab, LAG525, NIR178, capmatinib, MCS110, canakinumab
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Phase 2 Interventional Results available

Bicalutamide in Treating Patients With Metastatic Breast Cancer

NCT00468715
View directory record Official record
Conditions
Breast Cancer
Interventions
bicalutamide, diagnostic laboratory biomarker analysis, immunohistochemistry staining method
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2021
U.S. locations
8
States / cities
San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

NCT01227889
View directory record Official record
Conditions
Cancer
Interventions
GSK2118436, Dacarbazine (DTIC)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
11
States / cities
Birmingham, Alabama • Mobile, Alabama • La Jolla, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2017 · Synced Sep 11, 2026, 4:37 AM EDT
Terminated Phase 2 Interventional Results available

Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression

NCT03724968
View directory record Official record
Conditions
Metastatic Melanoma, Advanced Melanoma, Metastatic Melanoma Stratified by MHC-II Expression
Interventions
Nivolumab, Relatlimab, Ipilimumab
Drug
Lead sponsor
Elizabeth Davis
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Sep 11, 2026, 4:37 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer

NCT00765765
View directory record Official record
Conditions
Breast Cancer
Interventions
hydroxychloroquine, ixabepilone
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 120 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Hamilton, New Jersey • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma

NCT02644967
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
IMO-2125, Ipilimumab
Drug
Lead sponsor
Idera Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
10
States / cities
Tucson, Arizona • Tampa, Florida • Iowa City, Iowa + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Sep 11, 2026, 4:37 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of ConvitVax in Metastatic Breast Cancer

NCT06023277
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
ConvitVax
Biological
Lead sponsor
Jacinto Convit World Organization Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Pompano Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 4, 2023 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Phase 4 Interventional

Magseed Magnetic Marker in Locating Axillary Lymph Nodes in Patients With Breast Cancer Undergoing Surgery

NCT03038152
View directory record Official record
Conditions
Breast Carcinoma Metastatic in Lymph Node, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7
Interventions
Axillary Lymph Node Dissection, Localization, Medical Device
Procedure · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Phase 2 Interventional

An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer

NCT00580112
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Dexamethasone, Trabectedin
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
21
States / cities
Sedona, Arizona • Denver, Colorado • Torrington, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2014 · Synced Sep 11, 2026, 4:37 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

NCT02057133
View directory record Official record
Conditions
Breast Neoplasms
Interventions
LY2835219, Letrozole, Anastrozole, Tamoxifen, Exemestane, Everolimus, Trastuzumab, LY3023414, Fulvestrant, Pertuzumab, Loperamide, Endocrine therapy
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
13
States / cities
Rogers, Arkansas • La Jolla, California • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Phase 1Phase 2 Interventional

Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma

NCT00553306
View directory record Official record
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
therapeutic autologous lymphocytes, aldesleukin, cyclophosphamide, biopsy, immunohistochemistry staining method, flow cytometry, polymerase chain reaction
Biological · Drug · Procedure + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 14, 2017 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Phase 1 Interventional

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

NCT03821233
View directory record Official record
Conditions
HER2-expressing Cancers
Interventions
ZW49
Drug
Lead sponsor
Zymeworks BC Inc.
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
8
States / cities
Duarte, California • Tampa, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Sep 11, 2026, 4:37 AM EDT
Terminated Phase 2 Interventional Results available

Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer

NCT01873833
View directory record Official record
Conditions
HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
capecitabine, cyclophosphamide, lapatinib ditosylate, trastuzumab, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Phase 1 Interventional

Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer

NCT01352884
View directory record Official record
Conditions
Cancer
Interventions
AMP-224
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
4
States / cities
Detroit, Michigan • New York, New York • Huntersville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2016 · Synced Sep 11, 2026, 4:37 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma

NCT03297463
View directory record Official record
Conditions
Metastatic Melanoma, Pulmonary Metastases, Hepatic Metastases, Brain Metastases
Interventions
Interleukin-2 & Ipilimumab (P-Ib), Interleukin-2 & Ipilimumab (P-II)
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 11, 2026, 4:37 AM EDT